These reports suggest potential stage-dependent expression of 5α-reductase type in the prostate from SRD5A2 to SRD5A1 and SRD5A3, which is consistent with the fact that the use of 5α-reductase inhibitors is more relevant in early than in more advanced prostate cancers. Here, SRD5A1 is linked to prostate carcinoma.